
RAPP Stock Forecast & Price Target
RAPP Analyst Ratings
Bulls say
Rapport Therapeutics is a clinical-stage biotechnology company developing small molecule medications for neurological and psychiatric conditions. The company's lead asset RAP-219, an AMPA modulator, has shown a longer half-life of ~22 days and demonstrated sustained and improved seizure control in follow-up period data. Additionally, RAP-219 has potential to match the efficacy of other high benchmark treatments for focal onset seizures. The company also has a logical expansion opportunity in bipolar mania, with potential for success in both its epilepsy and bipolar mania programs.
Bears say
Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders. Despite positive data and a promising pipeline, the company has yet to bring a product to market and its financials are lacking, with a low cash position and no revenue. Additionally, the competition in these therapeutic areas is high, making it challenging for Rapport Therapeutics to successfully penetrate the market.
This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RAPP Analyst Forecast & Price Prediction
Start investing in RAPP
Order type
Buy in
Order amount
Est. shares
0 shares